Our History Since
2015
  • 2021

    In April, the antibody production site in Zhuhai International Health Park was completed and officially put into operation; completed Round A Financing of nearly RMB 450 million; in August, completed Round A+ Financing of RMB 700 million.

  • 2020

    In November, the world's first fully human monoclonal antibody against tetanus toxin, developed independently, entered phase I clinical trials.

  • 2019

    In April, reached a strategic cooperation agreement with WuXi Biologics; In November, entered into a regional license agreement with Changchun BCHT Bio regarding the fully human monoclonal antibody against tetanus toxin.

  • 2018

    In September, completed Pre-A round of financing of RMB 200 million.

  • 2017

    In May, the fully human monoclonal antibody new drug development center was put into operation.

  • 2016

    In September, selected as an Innovation and Entrepreneurship Team in Zhuhai.

  • 2015


    On December 17, Trinomab Biotech Co., Ltd was officially registered.


2021

In April, the antibody production site in Zhuhai International Health Park was completed and officially put into operation; completed Round A Financing of nearly RMB 450 million; in August, completed Round A+ Financing of RMB 700 million.

2020

In November, the world's first fully human monoclonal antibody against tetanus toxin, developed independently, entered phase I clinical trials.

2019

In April, reached a strategic cooperation agreement with WuXi Biologics; In November, entered into a regional license agreement with Changchun BCHT Bio regarding the fully human monoclonal antibody against tetanus toxin.

2018

In September, completed Pre-A round of financing of RMB 200 million.

2017

In May, the fully human monoclonal antibody new drug development center was put into operation.

2016

In September, selected as an Innovation and Entrepreneurship Team in Zhuhai.

2015


On December 17, Trinomab Biotech Co., Ltd was officially registered.


Ceremony of signing strategic cooperation with WuXi Biologics
The antibody production site of Trinomab in the Health Park completed
About Construction of the Antibody Production Site of Trinomab
High-tech Enterprise
Unicorn Potential Enterprise
Top 100 Growing Enterprises
Enterprise of Integrity
Guangdong Engineering Technology Research Center